PURE Bioscience, Inc. (OTCMKTS:PURE) Short Interest Down 14.7% in April
PURE Bioscience, Inc. (OTCMKTS:PURE) Short Interest Down 14.7% in April
PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) was the recipient of a significant drop in short interest in April. As of April 15th, there was short interest totalling 6,400 shares, a drop of 14.7% from the March 31st total of 7,500 shares. Based on an average daily volume of 131,500 shares, the days-to-cover ratio is presently 0.0 days.
Pure Bioscience，Inc.(場外交易平臺：Pure-Get Rating)是4月份空頭股數價格大幅下降的接受者。截至4月15日，空頭股數共有6,400股，較3月31日的7,500股減少14.7%。以日均成交量131,500股計算，目前天數與回補比率為0.0天。
PURE Bioscience Price Performance
純生物科學性價比
PURE stock remained flat at $0.09 during mid-day trading on Friday. The business's fifty day moving average is $0.13 and its 200 day moving average is $0.14. The firm has a market capitalization of $10.02 million, a P/E ratio of -2.25 and a beta of 0.21. PURE Bioscience has a one year low of $0.07 and a one year high of $0.24.
在週五午盤交易中，純股票持平於0.09美元。該業務的50日移動均線切入位為0.13美元，200日移動均線切入位為0.14美元。該公司市值為1,002萬美元，本益比為-2.25，貝塔係數為0.21。Pure Bioscience的一年低點為0.07美元，一年高位為0.24美元。
PURE Bioscience (OTCMKTS:PURE – Get Rating) last posted its quarterly earnings results on Friday, March 17th. The company reported ($0.01) earnings per share for the quarter. PURE Bioscience had a negative net margin of 228.72% and a negative return on equity of 142.15%. The company had revenue of $0.40 million during the quarter.
Pure Bioscience(OTCMKTS：Pure-Get Rating)上一次公佈季度收益是在3月17日星期五。該公司公佈了本季度每股收益(0.01美元)。純生物科學公司的淨利潤率為負228.72%，淨資產回報率為負142.15%。該公司本季度的收入為40萬美元。
Institutional Inflows and Outflows
機構資金流入和流出
An institutional investor recently bought a new position in PURE Bioscience stock. IFG Advisory LLC bought a new position in shares of PURE Bioscience, Inc. (OTCMKTS:PURE – Get Rating) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 809,809 shares of the company's stock, valued at approximately $161,000. IFG Advisory LLC owned 0.92% of PURE Bioscience at the end of the most recent quarter. Institutional investors own 0.92% of the company's stock.
一家機構投資者最近買入了一隻新的純生物科學股票頭寸。根據IFG Consulting LLC最近提交給美國證券交易委員會(Securities And Exchange Commission)的檔案，該公司在第三季度購買了Pure Bioscience，Inc.(OTCMKTS：Pure-Get Rating)股票的新頭寸。該基金購買了809,809股該公司股票，價值約161,000美元。截至最近一個季度末，IFG Consulting LLC擁有Pure Bioscience 0.92%的股份。機構投資者持有該公司0.92%的股票。
PURE Bioscience Company Profile
Pure Bioscience公司簡介
(Get Rating)
(獲取評級)
PURE Bioscience, Inc engages in the discovery, development, and commercialization of proprietary antimicrobial products for pathogen and hygienic control. It offers silver dihydrogen citrate-based disinfecting and sanitizing products. The company was founded by Michael L. Krall on August 24, 1992 and is headquartered in Rancho Cucamonga, CA.
Pure Bioscience，Inc.致力於發現、開發和商業化用於病原體和衛生控制的專有抗菌產品。它提供以檸檬酸二氫銀為基礎的消毒和消毒產品。該公司由Michael L.Krall於1992年8月24日創立，總部設在加利福尼亞州的蘭喬庫卡蒙加。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on PURE Bioscience (PURE)
- How to Invest in the Top Grocery Stocks for This Year
- Array Technologies Brings Solar Flare To 2023 Earnings Forecast
- Best Bank Stocks to Invest in Ahead of Rising Interest Rates
- How to Invest in Farmland: 7 Simple Ways
- ExxonMobil Gushes To New Highs
- 免費獲取StockNews.com關於純生物科學的研究報告(PURE)
- 如何投資今年最受歡迎的食品雜貨股
- 陣列技術將太陽耀斑帶到2023年收益預測
- 利率上升前最適合投資的銀行股
- 如何投資農田：7個簡單的方法
- 埃克森美孚股價創新高
Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《純生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Pure Bioscience和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。